Study Background
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, represents a significant and life-threatening complication in cancer patients. Among gynecologic malignancies, endometrial cancer is increasingly prevalent, yet data on VTE incidence in this population, particularly those undergoing systemic chemotherapy, remain limited. The prothrombotic state induced by malignancy and systemic therapy contributes to elevated VTE risk, impacting morbidity, mortality, and treatment outcomes. Identifying specific risk factors is crucial to enable effective prophylactic interventions and improve patient management.
